The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
893
April 2, 1993
View Complete Issue         Table of Contents 2019 
Atovaquone for Pneumocystis Carinii Pneumonia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Atovaquone for Pneumocystis Carinii Pneumonia
April 2, 1993 (Issue: 893)
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Atovaquone for Pneumocystis Carinii Pneumonia
Article code: 893b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.